Mylan To Enter Japanese Market , CEO Says
This article was originally published in PharmAsia News
American generic drug giant Mylan plans to expand into the Japanese market, Mylan CEO Robert J Coury announced during a press briefing in Tokyo. Coury said that Mylan will take Japanese market needs into consideration and start by supplying drug materials to Japanese pharmaceutical companies. Regarding a possible buyout of a Japanese generic drug maker, Coury commented that Mylan considers it as one option, but that an acquisition is not the only way to capture market share. Ranked as the world's number three generic drug maker, Mylan has commercial operations in 92 countries and sales of $4.2 billion in 2007. (Click here for more - Japanese language
You may also be interested in...
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Given concerns about completing Phase III trials, advisory committee member asks whether US FDA has considered ‘the possibility of an expanded access protocol,’ but agency official points to added complexity that comes with the pathway; bioethics experts talk to the Pink Sheet about pros and cons of expanded access vs. EUA pathways.